This Week Last Year in Medtech: Oct. 30 – Nov. 5This Week Last Year in Medtech: Oct. 30 – Nov. 5
See what Abiomed, Stryker, and Boston Scientific were up to this time last year.

Abiomed Struggles with Delta Variant and Hospital Labor Shortages
The Danvers, MA-based company trimmed FY22 outlook by $20 million.
Stryker Struck by Q3 Double Whammy: Delta and Hospital Staffing Shortages
Companies across the medical device industry were impacted by a common double whammy in the third quarter, and Stryker was not immune.
Boston Sci Scores Critical Win in Patent Dispute with Nevro
A Delaware jury has ordered Nevro to pay Boston Scientific $20 million regarding the infringement of two patents for spinal cord stimulation technology.
COVID-19 Diagnostics Still Play a Huge Role in Hologic’s Earnings
The Waltham, MA-based was able to beat consensus. Will its success herald even more M&A.
Is the New CMS Ruling a Win for iRhythm?
Will this fee decision benefit the San Francisco, CA-based company in the long run?
Is Integra's Breast Reconstruction PMA Doomed?
Despite getting shot down by a recent FDA advisory panel, Integra's management team still seems confident that the agency will ultimately approve SurgiMend for post-mastectomy breast reconstruction.
Measuring the Influence of FDA Advisory Committee Recommendations on Approval Decisions
The agency tends to agree with advisory committee recommendations, but not always.
About the Author
You May Also Like